ALMDT.PA (Median Technologies SA) down 18.97% to €5.34 intraday 16 Feb 2026: implications for EURONEXT traders

The ALMDT.PA stock is trading sharply lower intraday after a -18.97% move to €5.34 on 16 Feb 2026, making it one of EURONEXT’s top losers. Volume is elevated at 1,075,181 shares versus an average of 459,151, highlighting active selling. The drop follows a gap from yesterday’s €6.59 close and leaves the share price well above the 52-week low but below the 50-day average, forcing traders to reassess risk on this Healthcare medical-device software name.

ALMDT.PA stock: intraday price action and drivers

ALMDT.PA stock fell from an open of €5.48 to a day low of €4.97 before recovering to €5.34, a near €1.25 decline on the session. The spike in volume to 1,075,181 shares, nearly 4.20x relative volume, suggests stop-loss and momentum selling dominated the session. There is no single public announcement today; market reaction looks linked to recent sentiment and technical levels rather than new company fundamentals.

ALMDT.PA stock: fundamentals and valuation snapshot

Median Technologies SA (ALMDT.PA) reports EPS -€1.16 and a negative PE of -4.71, reflecting losses on the income statement. Market cap is about €200,150,452.00 with 36,657,592 shares outstanding and price-to-sales near 8.59. The company’s current ratio 0.35 and negative operating cash flow per share underscore liquidity pressure versus peers in Healthcare Medical – Devices.

ALMDT.PA stock: technicals and short-term outlook

Technically, ALMDT.PA stock sits below yesterday’s close and above the 200-day average of €2.97 but below its 50-day average of €4.27 on a closing basis. Momentum indicators show RSI 52.34 and ADX 42.50, signalling a strong trend with neutral momentum. Traders should watch support near today’s low €4.97 and resistance at the intraday high €5.60 for short-term setups.

ALMDT.PA stock: Meyka AI grade and model forecast

Meyka AI rates ALMDT.PA with a score of 68.89/100 — Grade: B (HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus and forecasts. Meyka AI’s forecast model projects a yearly price of €2.91, implying an approximate downside of -45.44% versus the current €5.34; forecasts are model-based projections and not guarantees.

ALMDT.PA stock: catalysts, risks and sector context

Primary catalysts for upside would be clearer revenue growth, improved cash flow and positive trial or contract updates for the iBiops platform. Key risks include continued operating losses, a low liquidity buffer, and valuation compression in the Healthcare sector where peers trade at higher multiples. Sector performance shows Healthcare modestly underperforming recent weeks, which can amplify downside for smaller med-tech names on negative flows.

ALMDT.PA stock: trading considerations and scenario targets

For traders, a conservative scenario places a near-term support target at €4.97 and a recovery resistance target at €5.60; a breakdown below €4.97 increases the chance of revisiting the 52-week low €1.19 in extreme stress. For bulls, a constructive re-entry would require sustained volumes above 459,151 average and confirmed cash-flow improvement; realistic price targets from technical and model mixes range from €3.00 to €7.27 depending on recovery speed.

Final Thoughts

ALMDT.PA stock is a clear intraday top loser on 16 Feb 2026 after a -18.97% move to €5.34 on heavy volume. The company shows mixed signals: meaningful revenue per share but negative EPS and tight liquidity metrics, including a current ratio of 0.35 and negative cash-flow per share. Meyka AI’s forecast model projects a yearly price of €2.91, implying a -45.44% downside from today’s level; forecasts are model-based projections and not guarantees. Given the grade B (HOLD) from Meyka AI and the risk of further downside, active traders should prioritise tight risk controls and watch official updates, upcoming earnings on 2026-04-23, and any clinical or commercial announcements. Long-term investors must weigh Median Technologies SA’s AI imaging platform potential against near-term balance-sheet and margin pressures. For real-time tracking, see our ALMDT.PA monitoring page on Meyka AI for live signals and updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.